



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C08G 77/448, 18/61, 18/44, C08L 83/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/54242</b>  <b>(43) International Publication Date:</b> 3 December 1998 (03.12.98)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <b>(21) International Application Number:</b> PCT/AU98/00375   <b>(22) International Filing Date:</b> 20 May 1998 (20.05.98)   <b>(30) Priority Data:</b>            PO 7002                      26 May 1997 (26.05.97)                      AU   <b>(71) Applicant (for all designated States except US):</b> CARDIAC CRC NOMINEES PTY. LTD. [AU/AU]; Royal North Shore Hospital, Block 4, Level 3, St. Leonards, NSW 2065 (AU).   <b>(72) Inventors; and</b>  <b>(75) Inventors/Applicants (for US only):</b> GUNATILLAKE, Pathiraja, Arachchillage [AU/AU]; 8 Katoomba Drive, Mulgrave, VIC 3170 (AU). MEIJS, Gordon, Francis [AU/AU]; 3 Henty Street, Murrumbreena, VIC 3163 (AU).   <b>(74) Agent:</b> CARTER SMITH &amp; BEADLE; 2 Railway Parade, P.O. Box 557, Camberwell, VIC 3124 (AU).         </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).   <b>Published</b>  <i>With international search report.</i> </td> </tr> </table>			<b>(21) International Application Number:</b> PCT/AU98/00375  <b>(22) International Filing Date:</b> 20 May 1998 (20.05.98)  <b>(30) Priority Data:</b> PO 7002                      26 May 1997 (26.05.97)                      AU  <b>(71) Applicant (for all designated States except US):</b> CARDIAC CRC NOMINEES PTY. LTD. [AU/AU]; Royal North Shore Hospital, Block 4, Level 3, St. Leonards, NSW 2065 (AU).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GUNATILLAKE, Pathiraja, Arachchillage [AU/AU]; 8 Katoomba Drive, Mulgrave, VIC 3170 (AU). MEIJS, Gordon, Francis [AU/AU]; 3 Henty Street, Murrumbreena, VIC 3163 (AU).  <b>(74) Agent:</b> CARTER SMITH & BEADLE; 2 Railway Parade, P.O. Box 557, Camberwell, VIC 3124 (AU).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(21) International Application Number:</b> PCT/AU98/00375  <b>(22) International Filing Date:</b> 20 May 1998 (20.05.98)  <b>(30) Priority Data:</b> PO 7002                      26 May 1997 (26.05.97)                      AU  <b>(71) Applicant (for all designated States except US):</b> CARDIAC CRC NOMINEES PTY. LTD. [AU/AU]; Royal North Shore Hospital, Block 4, Level 3, St. Leonards, NSW 2065 (AU).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GUNATILLAKE, Pathiraja, Arachchillage [AU/AU]; 8 Katoomba Drive, Mulgrave, VIC 3170 (AU). MEIJS, Gordon, Francis [AU/AU]; 3 Henty Street, Murrumbreena, VIC 3163 (AU).  <b>(74) Agent:</b> CARTER SMITH & BEADLE; 2 Railway Parade, P.O. Box 557, Camberwell, VIC 3124 (AU).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>			
<b>(54) Title:</b> SILICON-BASED POLYCARBONATES				
$  \begin{array}{c}  \begin{array}{c} R_1 \\   \\ A-R_5-Si \\   \\ R_3 \end{array} - \left( \begin{array}{c} R_2 \\   \\ R_7-Si \\   \\ R_4 \end{array} \right)_n - R_6 - O - \overset{\overset{O}{\parallel}}{C} - \left[ \begin{array}{c} R_1 \\   \\ R_5-Si \\   \\ R_3 \end{array} - \left( \begin{array}{c} R_2 \\   \\ R_7-Si \\   \\ R_4 \end{array} \right)_n - R_6 - O - \overset{\overset{O}{\parallel}}{C} - O - \begin{array}{c} R_1 \\   \\ R_5-Si \\   \\ R_3 \end{array} - \left( \begin{array}{c} R_2 \\   \\ R_7-Si \\   \\ R_4 \end{array} \right)_n - R_6 - \right]_x \\  \left( \begin{array}{c} O-R_8 \end{array} \right)_y - \left( \begin{array}{c} O \\   \\ O-C-O-R_9 \end{array} \right)_z - O - \overset{\overset{O}{\parallel}}{C} - O - \begin{array}{c} R_1 \\   \\ R_5-Si \\   \\ R_3 \end{array} - \left( \begin{array}{c} R_2 \\   \\ R_7-Si \\   \\ R_4 \end{array} \right)_n - R_6 - A  \end{array}  \quad (I)  $				
<b>(57) Abstract</b>  <p>A silicon-based polycarbonate of formula (I): wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>8</sub> and R<sub>9</sub> are same or different and selected from hydrogen or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical; R<sub>7</sub> is a divalent linking group or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical; A is an endcapping group; n, y and z are integers of 0 or more; and x is an integer of 0 or more.</p>				

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## SILICON-BASED POLYCARBONATES

The present invention generally relates to silicon-based polycarbonates, processes for their preparation and their use in the synthesis of copolymers, in particular segmented copolymers such as polyurethanes for biomedical applications.

Segmented copolymers typically derive good mechanical properties from the separation of microphases caused by immiscibility of the segments. For example, it is known that in thermoplastic polyurethane elastomers, the so-called "hard" and "soft" segments have limited miscibility and separate to form microdomains. Many of the properties of polyurethane elastomers can be rationalised in terms of a semi-crystalline hard domain providing a reinforcement or filler-like effect within a soft matrix. The soft matrix or domain, most frequently comprises a poly(alkylene ether) or polyester chain of molecular weight within the range of about 500 to 2000. Such short polymer chains are generally terminated with hydroxyl groups and known as "macrodiols".

The structure of the macrodiol plays a significant role in determining the performance of the segmented copolymer. Polyester-based macrodiols generally give good mechanical properties, but poor resistance to degradation in harsh environments experienced in for example marine and biomedical applications.

Polyether macrodiols offer enhanced stability, but are not suitable for the synthesis of extremely soft materials, particularly when high stability is also required.

Polysiloxane-based polymers, especially polydimethyl siloxane (PDMS) exhibit characteristics such as low glass transition temperatures, good thermal, oxidative and hydrolytic stabilities and low surface energies. These properties would be desirable in the macrodiol-derived component of a segmented copolymer. In addition, they display good compatibility with biological tissues and fluids and low toxicity. For these reasons, PDMS has found particular

application in the construction of medical devices, especially implantable devices. However, polymers derived from PDMS do not generally exhibit good tensile properties such as flexural strength or abrasion resistance.

Considerable efforts have gone into finding a means for incorporating  
5 low molecular weight PDMS segments into segmented copolymers such as polyurethanes. These efforts have mainly focussed on achieving clarity, processability and a good balance of mechanical properties<sup>1</sup>. However, no completely successful attempts have been disclosed. Speckhard *et al*<sup>2</sup> have indicated that as a result of large differences in solubility parameters of PDMS  
10 and most conventional hard segments, PDMS-based polyurethanes are likely to be highly phase separated materials characteristic of poor mechanical properties. As a result of this large difference in polarity between hard and soft segments, it is anticipated that premature phase separation occurs during synthesis and there is compositional heterogeneity and overall low molecular weight. In  
15 addition, there appears to be an optimal degree of mixing at the interface between soft and hard domains, with extremely sharp interfaces leading to a low degree of mechanical coupling between the two domains and resulting poor strength. Thus it is understood that, for example, PDMS-based polyurethanes generally exhibit poor mechanical properties. Typically, the tensile strength and  
20 elongation at break are about 7 MPa and 200%, respectively<sup>2</sup>.

Polycarbonate macrodiols have also been used as reactive ingredients in the synthesis of block and segmented copolymer systems, in particular high performance polyurethanes. Processes for preparing polycarbonate macrodiols based on a range of bishydroxy alkylene compounds are disclosed in JP  
25 62,241,920 (Toa Gosei Chemical Industry Co. Ltd.), JP 64,01,726 (Dainippon Ink and Chemicals, Inc.), JP 62,187,725 (Daicel Chemical Industries, Ltd.) DE 3,717,060 (Bayer A.G.), US 4,105,641 (Bayer Aktiengesellschaft), US 4,131,731 (Beatrice Foods Company) and US 5,171,830 (Arco Chemical Technology).


30 The most common alkylenediol described in these patent specifications

is 1,6-hexanediol.

Although polycarbonate macrodiols are generally classified under polyesters, the corresponding polyurethanes exhibit hydrolytic stabilities comparable or in some cases superior to polyetherurethanes<sup>3</sup>. They also possess  
5 high tensile strength and toughness. These properties are attributed to the high level of phase mixing, promoted by intermolecular hydrogen bonding involving the hard segment urethane hydrogens and the carbonate functional groups of the soft segment. The hydrogen bonding is also partly responsible for the relatively poor elastomeric properties such as low flexibility and high durometer hardness  
10 of polyurethanes based on polycarbonate macrodiols. These properties are in contrast to those of the non polar macrodiol based polyurethanes, such as those based on siloxanes.

A requirement accordingly exists to develop silicon-based macrodiols for use as building blocks of segmented copolymers such as polyurethanes with  
15 structural features that allow good compatibility and mechanical properties. Suitable macrodiols would retain the advantages of silicon-based polymers such as flexibility, low temperature performance, stability and in some cases biocompatibility. The disadvantages of poor mechanical properties will preferably be avoided so that the silicon-based macrodiols can form part of  
20 materials which can be used in various demanding applications, particularly the biomedical field.

According to one aspect of the present invention there is provided a silicon-based polycarbonate of the formula (I):



(I)

wherein

$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_8$  and  $R_9$  are same or different and selected from hydrogen or an optionally substituted straight chain, branched or cyclic, saturated or  
 5 unsaturated hydrocarbon radical;

$R_7$  is a divalent linking group or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical;

A is an endcapping group;

n, y and z are integers of 0 or more; and

10 x is an integer of 0 or more.

The hydrocarbon radical for substituents  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  may include alkyl, alkenyl, alkynyl, aryl or heterocyclyl radicals. It will be appreciated that the equivalent radicals may be used for substituents  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$  and  $R_9$  except that the reference to alkyl, alkenyl and alkynyl should be to alkylene, alkenylene and  
 15 alkynylene, respectively. In order to avoid repetition, only detailed definitions of alkyl, alkenyl and alkynyl are provided hereinafter.

The term "alkyl" denotes straight chain, branched or mono- or poly- cyclic alkyl, preferably  $C_{1-12}$  alkyl or cycloalkyl. Examples of straight chain and branched alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, amyl, isoamyl, sec-amyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, pentyl, hexyl, 4-  
 20



methypentyl, 1-methypentyl, 2-methypentyl, 3-methypentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, 1,1,2-trimethylpropyl, heptyl, 5-methylhexyl, 1-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl, octyl, 6-methylheptyl, 1-methylheptyl, 1,1,3,3-tetramethylbutyl, nonyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-methyloctyl, 1-, 2-, 3-, 4- or 5-ethylheptyl, 1-, 2- or 3-propylhexyl, decyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- and 8-methylnonyl, 1-, 2-, 3-, 4-, 5- or 6-ethyloctyl, 1-, 2-, 3- or 4-propylheptyl, undecyl 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-methyldecyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-ethylnonyl, 1-, 2-, 3-, 4- or 5-propyloctyl, 1-, 2- or 3-butylheptyl, 1-pentylhexyl, dodecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-methylundecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-ethyldecyl, 1-, 2-, 3-, 4-, 5- or 6-propylnonyl, 1-, 2-, 3- or 4-butyloctyl, 1,2-pentylheptyl and the like. Examples of cyclic alkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl and the like.

The term "alkenyl" denotes groups formed from straight chain, branched or mono- or poly-cyclic alkenes including ethylenically mono- or poly-unsaturated alkyl or cycloalkyl groups as defined above, preferably C<sub>2-12</sub> alkenyl. Examples of alkenyl include vinyl, allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3 heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl, 1,3,5,7-cycloocta-tetraenyl and the like.

The term "alkynyl" denotes groups formed from straight chain, branched, or mono- or poly-cyclic alkynes. Examples of alkynyl include ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 10-undecynyl, 4-ethyl-1-octyn-3-yl, 7-dodecynyl, 9-dodecynyl, 10-dodecynyl, 3-methyl-1-dodecyn-3-yl, 2-tridecynyl, 11-tridecynyl, 3-tetradecynyl, 7-hexadecynyl, 3-octadecynyl and the like.

The term "aryl" denotes single, polynuclear, conjugated and fused residues of aromatic hydrocarbons. Examples of aryl include phenyl, biphenyl, terphenyl, quaterphenyl, phenoxyphenyl, naphthyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl, dibenzanthracenyl, phenanthrenyl and the like.

5 The term "heterocyclyl" denotes mono- or poly-cyclic heterocyclyl groups containing at least one heteroatom selected from nitrogen, sulphur and oxygen. Suitable heterocyclyl groups include N-containing heterocyclic groups, such as, unsaturated 3 to 6 membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl,  
10 pyrazinyl, pyridazinyl, triazolyl or tetrazolyl; saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, such as pyrrolidinyl, imidazolidinyl, piperidino or piperazinyl; unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, such as, indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl or  
15 tetrazolopyridazinyl; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, such as, pyranyl or furyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms, such as, thienyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, oxazolyl, isoazolyl or oxadiazolyl; saturated 3 to 6-  
20 membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, morpholinyl; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, benzoxazolyl or benzoxadiazolyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms, such as thiazolyl or thiadiazolyl;  
25 saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms, such as, thiadiazolyl; and unsaturated condensed heterocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms, such as benzothiazolyl or benzothiadiazolyl.

In this specification, "optionally substituted" means that a group may or may  
30 not be further substituted with one or more groups selected from oxygen, nitrogen,




sulphur, alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, alkynyloxy, aryloxy, carboxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, azido, amino, alkylamino, alkenylamino, alkynylamino, arylamino, benzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, acylamino, acyloxy, aldehydo, alkylsulphonyl, arylsulphonyl, alkylsulphonylamino, arylsulphonylamino, alkylsulphonyloxy, arylsulphonyloxy, heterocyclyl, heterocycloxy, heterocyclylamino, haloheterocyclyl, alkylsulphenyl, arylsulphenyl, carboalkoxy, carboaryloxy, mercapto, alkylthio, arylthio, acylthio and  
5 the like.  
10

Suitable divalent linking groups for  $R_7$  include O, S and NR wherein R is hydrogen or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical.

Preferably z is an integer of 0 to about 50 and x is an integer of 1 to about 50. Suitable values for n include 0 to about 20, more preferably 0 to about 10. Preferred values for y are 0 to about 10, more preferably 0 to about 2.  
15

The term "endcapping group" is used herein in its broadest sense and includes reactive functional groups or groups containing reactive functional groups. Suitable examples of reactive functional groups are alcohols, carboxylic acids, aldehydes, ketones, esters, acid halides, acid anhydrides, amines, imines, thio, thioesters, sulphonic acid and epoxides. Preferably the reactive functional group is an alcohol or an amine, more preferably an alcohol.  
20

A preferred polycarbonate is a compound of the formula (I) wherein A is OH which is a polycarbonate macrodiol of the formula (1a):



(Ia)


wherein

$R_1$  to  $R_9$ ,  $n$ ,  $y$ ,  $x$  and  $z$  are as defined in formula (I) above.

Particularly preferred polycarbonate macrodiols are compounds of the formula (Ia) wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are methyl,  $R_8$  is ethyl,  $R_9$  is hexyl,  $R_5$  and  $R_6$  are propyl or butyl and  $R_7$  is O or  $-\text{CH}_2\text{-CH}_2-$ , more preferably  $R_5$  and  $R_6$  are propyl when  $R_7$  is O and  $R_5$  and  $R_6$  are butyl when  $R_7$  is  $-\text{CH}_2\text{-CH}_2-$ . The preferred molecular weight range of the polycarbonate macrodiol is about 400 to about 5000, more preferably about 400 to about 2000.

The present invention also provides a process for preparing the silicon-based polycarbonate macrodiol of the formula (Ia) as defined above which includes reacting a source of carbonate with either:

- (i) a silicon-based diol of the formula (II)



(II)

wherein

$R_1$  to  $R_7$  and  $n$  are as defined in formula (I) above; or

- (ii) the silicon-based diol of the formula (II) defined in (i) above and a  
5 non-silicon based diol of the formula (III):



(III)

wherein

$R_9$  is as defined above in formula (I).

- 10 This process may be extended to the preparation of the silicon-based polycarbonate of the formula (I) by including the additional step of converting the hydroxyl groups in the macrodiol of the formula (1a) into other reactive functional groups. This conversion step can be achieved using procedures known in the art such as oxidation to give a dicarboxylic acid, conversion to an amine using the  
15 Gabriel procedure or reaction with an endcapping agent, for example, diisocyanate, dicarboxylic acid, cyclic anhydride or the like.

The source of carbonate may be a carbonate compound or two or more reagents which when combined produce carbonate or a carbonate compound. Suitable carbonate compounds include cyclic carbonates such as alkylene carbonates  
20 for example ethylene or propylene carbonate and linear carbonates such as dialkyl or diaryl carbonates, for example, dimethyl carbonate, diethyl carbonate or diphenyl carbonate. Preferably the source of carbonate has a low molecular weight because of the ease of removal of the condensation by-product from the reaction mixture.

The silicon-based diols of the formula (II) may be obtained as commercially  
25 available products. For example 1,3-bis(hydroxypropyl)-1,1,3,3-tetramethyldisiloxane and 1,3-bis(hydroxybutyl)-1,1,3,3-tetramethyldisiloxane are available from Shin Etsu or Silar Laboratories. Others can be prepared by using the appropriate disilane compounds and hydroxy terminated olefinic compounds using a hydrosilylation reaction<sup>4</sup>.

- 30 It will be appreciated that the diol of formula (II) can be used separately or

as a mixture containing two or more structurally different diols in the preparation of the polycarbonates according to the present invention. The presence of silicon or siloxy radicals in the diol imparts hydrophobic and flexibility characteristics which results in improved elastomeric and degradation resistance in copolymers produced  
5 from these polycarbonates.


In another embodiment, non-silicon based diols of the formula (III) can be used in combination with the silicon-based diols of the formula (II) for the preparation of polycarbonates. Preferably, the non-silicon based diol is an aliphatic dihydroxy compound, such as, alkylene diols, for example, 1,4-butanediol, 1,6-  
10 hexanediol, diethyleneglycol, triethyleneglycol, 1,4-cyclohexanediol or 1,4-cyclohexanedimethanol. It has been found that when a silicon-containing diol and an alkylene diol are reacted, the resulting polycarbonate is generally a random copolycarbonate. Accordingly, polycarbonates having a broad range of properties can be prepared by choosing different ratios of the two diols.

15 The process for preparing the polycarbonate is preferably a transesterification similar to that described in US 4,131,731 which is carried out in the presence of a transesterification catalyst. Examples of suitable catalysts include those disclosed in US 4,105,641 such as stannous octoate and dibutyl tin dilaurate.

It will be appreciated that other processes may be used to prepare the  
20 polycarbonate of the present invention such as those described by Eckert *et al*<sup>5</sup> which are incorporated herein by reference. Some of these processes include reacting the source of carbonate and the diol of the formula (II) with either phosgene (ClCOCl) or chloroformates, for example, Cl-COO-R'-OCOCl wherein R' is a divalent linking group or an optionally substituted straight chain, branched or cyclic, saturated or  
25 unsaturated hydrocarbon radical.

The polycarbonate of the present invention may be used in the preparation of copolymers such as copolyesters, copolyethercarbonates, copolyamides, copolyimides or segmented copolymers for example polyurethane or polyurethane urea elastomers.

Thus, the present invention further provides a copolymer which includes a  
30 silicon-based polycarbonate segment of the formula (Ib):



(Ib)

wherein

$R_1$  to  $R_9$ ,  $n$ ,  $y$ ,  $x$  and  $z$  are as defined in formula (I) above.

The polycarbonate of the present invention is particularly useful in preparing  
5 polyurethane elastomeric compositions.

According to a still further aspect of the present invention there is provided a polyurethane elastomeric composition which includes a silicon-based polycarbonate segment of the formula (Ib) defined above.

The polyurethane elastomeric compositions of the present invention may be  
10 prepared by any suitable known technique. A preferred method involves mixing the polycarbonate and a chain extender and then reacting this mixture with a diisocyanate. The initial ingredients are preferably mixed at a temperature in the range of about 45 to about 100°C, more preferably about 60 to about 80°C. If desired, a catalyst such as dibutyl tin dilaurate at a level of about 0.001 to about  
15 0.5 wt % based on the total ingredients may be added to the initial mixture. The mixing may occur in conventional apparatus or within the confines of a reactive extruder or continuous reactive injection molding machine.

Alternatively, the polyurethanes may be prepared by the prepolymer method which involves reacting a diisocyanate with the polycarbonate to form a prepolymer  
20 having terminally reactive diisocyanate groups. The prepolymer is then reacted with a chain extender.

Thus, the polyurethane elastomeric composition of the present invention may be further defined as comprising a reaction product of:

- (i) a silicon-based polycarbonate of the formula (I) defined above;
- (ii) a diisocyanate; and
- 5 (iii) a chain extender.

Preferably, the diisocyanate is selected from 4,4'-methylenediphenyl diisocyanate (MDI), methylene bis(cyclohexyl) diisocyanate (H12MDI), p-phenylene diisocyanate (p-PDI), trans-cyclohexane-1, 4-diisocyanate (CHDI) or a mixture of the cis and trans isomers, 1,6-hexamethylene diisocyanate (DICH), 2,4-toluene  
10 diisocyanate (2,4-TDI) or its isomers or mixtures thereof, p-tetramethylxylene diisocyanate (p-TMXDI) and m-tetramethylxylene diisocyanate (m-TMXDI). MDI is particularly preferred.

The chain extender is preferably selected from 1, 4-butanediol, 1, 6-hexanediol, 1, 8-octanediol, 1,9-nonanediol, 1,10-decanediol 1,4-cyclohexane  
15 dimethanol, p-xyleneglycol, 1,4-bis (2-hydroxyethoxy) benzene and 1,12-dodecanediol. 1, 4-butanediol is particularly preferred.

A particularly preferred polyurethane elastomeric composition of the present invention comprises a reaction product of:

- (i) compounds of the formula (Ia) wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are methyl,  
20  $R_8$  is ethyl,  $R_9$  is hexyl,  $R_5$  and  $R_6$  are propyl or butyl and  $R_7$  is O or -  
 $\text{CH}_2\text{-CH}_2\text{-}$ ;
- (ii) MDI; and
- (iii) 1,4-butanediol.

An advantage of the incorporation of the polycarbonate segment is the relative  
25 ease of processing of the polyurethane by conventional methods such as extrusion, injection and compression moulding without the need of added processing waxes. If desired, however, conventional polyurethane processing additives such as catalysts, antioxidants, stabilisers, lubricants, dyes, pigments, inorganic and/or organic fillers and reinforcing materials can be incorporated into the polyurethane during  
30 preparation. Such additives are preferably added to the polycarbonate.



The polycarbonate, diisocyanate and chain extender may be present in certain proportions. The preferred level of hard segment (i.e., diisocyanate and chain extender) in the composition is about 30 to about 60 wt %, more preferably 40 to 50 wt%.

5       The polyurethane elastomeric composition of the present invention is particularly useful in preparing materials having good mechanical properties, in particular biomaterials.

According to another aspect of the present invention there is provided a material having improved mechanical properties, clarity, processability and/or  
10 degradation resistance comprising a polyurethane elastomeric composition which includes a polycarbonate segment of the formula (Ib) defined above.

The present invention also provides use of the polyurethane elastomeric composition defined above as a material having improved mechanical properties, clarity, processability and/or degradation resistance.

15       The present invention further provides the polyurethane elastomeric composition defined above when used as a material having improved mechanical properties, clarity, processability and/or degradation resistance.

The mechanical properties which are improved include tensile strength, tear strength, abrasion resistance, Durometer hardness, flexural modulus and related  
20 measures of flexibility or elasticity.

The improved resistance to degradation includes resistance to free radical, oxidative, enzymatic and/or hydrolytic processes and to degradation when implanted as a biomaterial.

The improved processability includes ease of processing by casting such as  
25 solvent casting and by thermal means such as extrusion and injection molding, for example, low tackiness after extrusion and relative freedom from gels.

There is also provided a degradation resistant material which comprises the polyurethane elastomeric composition defined above.

The polyurethane elastomeric composition of the present invention shows  
30 good elastomeric properties. It should also have a good compatibility and stability

in biological environments, particularly when implanted *in vivo* for extended periods of time.

According to another aspect of the present invention there is provided an *in vivo* degradation resistant material which comprises the polyurethane elastomeric composition defined above.

The polyurethane elastomeric composition may also be used as a biomaterial. The term "biomaterial" is used herein in its broadest sense and refers to a material which is used in situations where it comes into contact with the cells and/or bodily fluids of living animals or humans.

The polyurethane elastomeric composition is therefore useful in manufacturing medical devices, articles or implants.

Thus, the present invention still further provides medical devices, articles or implants which are composed wholly or partly of the polyurethane elastomeric composition defined above.

The medical devices, articles or implants may include cardiac pacemakers and defibrillators, catheters, cannulas, implantable prostheses, cardiac assist devices, heart valves, vascular grafts, extra-corporeal devices, artificial organs, pacemaker leads, defibrillator leads, blood pumps, balloon pumps, A-V shunts, biosensors, membranes for cell encapsulation, drug delivery devices, wound dressings, artificial joints, orthopaedic implants and soft tissue replacements.

It will be appreciated that polyurethane elastomeric compositions having properties optimised for use in the construction of various medical devices, articles or implants will also have other non-medical applications. Such applications may include their use in the manufacture of artificial leather, shoe soles; cable sheathing; varnishes and coatings; structural components for pumps, vehicles, etc; mining ore screens and conveyor belts; laminating compounds, for example in glazing; textiles; separation membranes; sealants or as components of adhesives.

It will also be understood that the siloxane component of the polyurethane elastomeric composition by virtue of its dielectric properties will provide opportunities for use in electronic and electrical components and insulation.

Thus, the present invention extends to the use of the polyurethane elastomeric composition defined above in the manufacture of devices or articles.

The present invention also provides devices or articles which are composed wholly or partly of the polyurethane elastomeric composition defined above.

5 The invention will now be described with reference to the following examples. These examples are not to be construed as limiting the invention in any way.

In the examples, reference will be made to the accompanying drawings in which:

10 Fig. 1 shows differential scanning calorimetry (DSC) thermograms of polycarbonate macrodiols (a) 1,6-hexandiol based commercial polycarbonate, (b) macrodiol of Example 2 and (c) macrodiol of Example 1; and  
Fig. 2 shows DSC thermograms demonstrating well phase separated morphologies of polyurethanes based on silicon containing macrodiols (i) PU-  
15 1 based on a commercial polycarbonate macrodiol, (ii) PU-2 from macrodiol in Example 2 and (iii) PU-3 from macrodiol in Example 1.

### Example 1

Ethylene carbonate (50 g), 1,6-hexanediol (25 g), stannous-2-ethyl-hexanoate (0.13 g) and 1,3-bis(4-hydroxybutyl)-1,1,3,3-tetramethyldisiloxane (25 g) were  
20 placed in a 250 ml three-necked round bottom flask. The flask was then fitted with a fractionation column (filled with glass beads), distillation head, magnetic stirrer bar, condenser, nitrogen inlet and thermometer. The polymerisation was carried out in three stages. In the first stage, the reaction mixture was heated to 180°C under a nitrogen flow while maintaining a vacuum of 140 mmHg over a period of about  
25 4h. In the second stage, the reaction temperature was raised to 190°C while increasing the vacuum to 50 mmHg and the reaction was continued for 2 more hours. During this period, the vacuum was reduced to 10 mmHg, stepwise. About 75% of the total distillate was collected during the second stage. In the third stage, the temperature was raised to 200°C, the vacuum reduced to 5 mmHg with the

nitrogen flow stopped and the reaction was continued for a further 30 min. The reaction was stopped at the end of the third stage by removing the flask from the heating bath and allowing to cool to room temperature under ambient pressure. The progress of the polymerisation reaction was monitored by analysing a sample of the crude product by  $^1\text{H}$ -NMR spectroscopy and by size exclusion chromatography. The product polymer was a pale yellow viscous liquid. Yield of the crude polymer was 44.5g.

The crude macrodiol was dissolved in dichloromethane to make a 15 % solution and treated with charcoal to remove coloured impurities as well as the catalyst residues. The macrodiol obtained after evaporating the dichloromethane from the filtered solution was further purified by washing with boiling water to remove traces of ethylene glycol and unreacted ethylene carbonate. Boiling water (200 ml) was added to the polymer and stirred for 10 min, allowed to settle and the water was decanted off. This process was repeated three times. The final polymer was then dried at 80°C under vacuum (0.1 mmHg) for 15 h. The final yield was 40 g. The molecular weight of the macrodiol based on the hydroxyl number was 1220. The macrodiol was also analysed by DSC and the results are shown in Fig. 1.

### Example 2

A procedure similar to that in example 1 was followed, except that the polymerisation was carried out using ethylene carbonate and 1,3-bis(4-hydroxybutyl)-1,1,3,3-tetramethyldisiloxane (25 g). The product copolycarbonate macrodiol was isolated and purified by the procedure used in Example 1. The yield of the macrodiol was 18 g and the molecular weight based on hydroxyl number was 874. The macrodiol was also analysed by DSC and the results are shown in Fig. 1.

### Example 3

Three polyurethanes were prepared from 1,6-hexanediol based commercial polycarbonate macrodiol and the macrodiols obtained in examples 2 and 1. The polyurethanes were labelled PU-1, PU-2 and PU-3, respectively. Details of the

typical one-step polymerisation procedure used to prepare the polyurethanes is described below.

The pre-dried macrodiol prepared in Example 1 (25.00 g, MW 1220), 1,4-butanediol (3.055 g) and stannous 2-ethyl-hexanoate (0.004 g, 0.01-wt % of total solids) were placed in a 250 ml polypropylene beaker and degassed at 80°C in an oven under a vacuum of 2 mmHg for 1.5 h. Molten MDI (13.61 g) was weighed into a MDI wet tared 50 ml polypropylene beaker and quickly poured into the macrodiol mixture while rapidly stirring with a stainless steel spatula, under a nitrogen blanket. After stirring for 30 sec, the viscous polymer was poured onto a teflon coated metal pan and cured at 100°C (4h) in an oven under dry nitrogen. All three polyurethanes were analysed by DSC and the results are shown in Fig. 2. Tensile test results are shown in Table 1 below.

**Table 1**

Polyurethane	Hardness (Shore A)	Fail Stress (MPa)	Fail Strain (%)	Stress at 100% Elongation (MPa)	Youngs Modulus (MPa)
PU-1	85	40	180	20.1	144
PU-2	68	20	450	9.5	31
PU-3	74	33	300	13	31

## References

1. Yu *et al.*, *J. Polym. Sci Phys. Ed.*, 23, p 2319 (1985).
2. Speckhard *et. al.*, *Rubber Chem. Technol.*, 59, p 405 (1986).
3. Awater *et al.*, *Polyurethane Handbook*, 2nd ed, G. Oertel Ed., pp 22 and 67,


(1993).

4. Braun *et al.*, *Journal of Organic Chemistry*, Vol 332, pp 63-68, (1987).
  5. Eckert *et al.*, *Comprehensive Organic Functional Group Transformations*, Kastritzky *et al.*, Ed., Vol 6, pp 460-471 (1995).
- 5        It will be appreciated that further modifications and alterations may be made to the embodiment described above without departing from the scope or spirit of the present invention.



## CLAIMS:

1. A silicon-based polycarbonate of the formula (I):



(I)

wherein

- 5  $R_1, R_2, R_3, R_4, R_5, R_6, R_8$  and  $R_9$  are same or different and selected from hydrogen or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical;
- $R_7$  is a divalent linking group or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical;
- 10  $A$  is an endcapping group;
- $n, y$  and  $z$  are integers of 0 or more; and
- $x$  is an integer of 0 or more.
2. A silicon-based polycarbonate as claimed in claim 1 wherein  $z$  is an integer of 0 to 50.
- 15 3. A silicon-based polycarbonate as claimed in claim 1 or claim 2 wherein  $x$  is an integer of 1 to 50.
4. A silicon-based polycarbonate as claimed in any one of claims 1 to 3 wherein  $n$  is an integer of 0 to 20.
5. A silicon-based polycarbonate as claimed in claim 4 wherein  $n$  is an integer of 0 to 10.
- 20 6. A silicon-based polycarbonate as claimed in any one of claims 1 to 5

wherein y is an integer of 0 to 10.

7. A silicon-based polycarbonate as claimed in claim 6 wherein y is an integer of 0 to 2.

8. A silicon-based polycarbonate as claimed in any one of the preceding  
5 claims wherein the hydrocarbon radical for substituents  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ , and  $R_9$  include alkyl, alkenyl, alkynyl, aryl, or heterocyclyl radicals or equivalents of the alkyl, alkenyl or alkynyl radicals or the alkylene, alkylenylene or alkynylene where appropriate.

9. A silicon-based polycarbonate as claimed in claim 8 wherein said alkyl  
10 radical is a straight chain, a branched or mono-or poly-cyclic alkyl.

10. A silicon-based polycarbonate as claimed in claim 9 wherein said alkyl radical is a  $C_{1-12}$  alkyl or cycloalkyl radical.

11. A silicon-based polycarbonate as claimed in claim 9 wherein said methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, amyl, isoamyl, sec-amyl,  
15 1,2-dimethylpropyl, 1,1-dimethylpropyl, pentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, 1,1,2-trimethylpropyl, heptyl, 5-methylhexyl, 1-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl, octyl,  
20 6-methylheptyl, 1-methylheptyl, 1,1,3,3-tetramethylbutyl, nonyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-methyloctyl, 1-, 2-, 3-, 4- or 5-ethylheptyl, 1-, 2- or 3-propylhexyl, decyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- and 8-methylnonyl, 1-, 2-, 3-, 4-, 5- or 6-ethyloctyl, 1-, 2-, 3- or 4-propylheptyl, undecyl 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-methyldecyl, 1-, 2-, 3-,  
25 4-, 5-, 6- or 7-ethylnonyl, 1-, 2-, 3-, 4- or 5-propyloctyl, 1-, 2- or 3-butylheptyl, 1-pentylhexyl, dodecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-methylundecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-ethyldecyl, 1-, 2-, 3-, 4-, 5- or 6-propylnonyl, 1-, 2-, 3- or 4-butyloctyl, 1,2-pentylheptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.

30 12. A silicon-based polycarbonate as claimed in claim 8 wherein said

alkenyl radical includes groups formed from straight chain, branched or mono- or poly- cyclic alkenes.

13. A silicon-based polycarbonate as claimed in claim 12 wherein said alkenyl radical is a C<sub>2-12</sub> alkenyl.

5 14. A silicon-based polycarbonate as claimed in claim 12 wherein said alkenyl radical is an ethylenically mono- or poly- unsaturated alkyl or cyclo-alkyl group of those claimed in claim 11.

15. A silicon-based polycarbonate as claimed in claim 12 wherein said alkenyl radical is selected from vinyl, allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-  
10 methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3 heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl and 1,3,5,7-cycloocta-  
15 tetraenyl.

16. A silicon-based polycarbonate as claimed in claim 8 wherein said alkynyl radical includes group formed from straight chain, branched or mono- or polycyclic alkynes.

17. A silicon-based polycarbonate as claimed in claim 16 wherein said  
20 alkynyl radical is selected from ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 10-undecynyl, 4-ethyl-1-octyn-3-yl, 7-dodecynyl, 9-dodecynyl, 10-dodecynyl, 3-methyl-1-dodecyn-3-yl, 2-tridecynyl, 11-tridecynyl, 3-tetradecynyl, 7-hexadecynyl and 3-octadecynyl.

25 18. A silicon-based polycarbonate as claimed in claim 8 wherein said aryl radical includes single, polynuclear, conjugated and fused residues of aromatic hydrocarbons.

19. A silicon-based polycarbonate as claimed in claim 18 wherein said aryl radical includes phenyl, biphenyl, terphenyl, quaterphenyl, phenoxyphenyl, naphthyl,  
30 tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl,

dibenzanthracenyl, phenanthrenyl and the like.

20. A silicon-based polycarbonate as claimed in claim 8 wherein said heterocycl radical includes mono- or poly- cyclic heterocycl group containing at least one heteroatom selected from nitrogen, sulphur and oxygen.

5 21. A silicon-based polycarbonate as claimed in claim 20 wherein said heterocycl radical includes N-containing heterocyclic groups including unsaturated 3 to 6 membered heteromonocyclic groups containing 1 to 4 nitrogen atoms including pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl and tetrazolyl; saturated 3 to 6-membered heteromonocyclic  
10 groups containing 1 to 4 nitrogen atoms including pyrrolidinyl, imidazolidinyl, piperidino and piperazinyl; unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms including indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl and tetrazolopyridazinyl; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom including  
15 pyranyl and furyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms including thienyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, including oxazolyl, isoazolyl and oxadiazolyl; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms  
20 including morpholinyl; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms including benzoxazolyl and benzoxadiazolyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms including thiazolyl and thiadiazolyl; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms  
25 and 1 to 3 nitrogen atoms including thiadiazolyl; and unsaturated condensed heterocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms including benzothiazolyl and benzothiadiazolyl.


22. A silicon-based polycarbonate as claimed in any one of the preceding claims wherein said radicals are optionally substituted with one or more groups  
30 selected from oxygen, nitrogen, sulphur, alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl,

haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, alkynyloxy, aryloxy, carboxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, azido, amino, alkylamino, alkenylamino, alkynylamino, arylamino, benzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, acylamino, acyloxy, aldehydo, alkylsulphonyl, arylsulphonyl, alkylsulphonylamino, arylsulphonylamino, alkylsulphonyloxy, arylsulphonyloxy, heterocyclyl, heterocycloxy, heterocyclylamino, haloheterocyclyl, alkylsulphenyl, arylsulphenyl, carboalkoxy, carboaryloxy, mercapto, alkylthio, arylthio and acylthio.

23. A silicon-based polycarbonate as claimed in any one of the preceding claims wherein  $R_7$  includes O, S and NR wherein R is hydrogen or an optically substituted straight chain, branched or cyclic, saturated or unsaturated, hydrocarbon radical.

24. A silicon-based polycarbonate as claimed in any one of the preceding claims wherein A is an endcapping group including alcohols, carboxylic acids, aldehydes, ketones, esters, acid halides, acid anhydrides, amines, iminies, thio, thioesters, sulphonic acid and expoxides.

25. A silicon-based polycarbonate as claimed in any one of the preceding claims wherein A is OH which is a polycarbonate macrodiol of the formula (1a):



(1a)

R<sub>1</sub> to R<sub>9</sub>, n, y, x and z are as defined in formula (I) above.

26. A silicon-based polycarbonate as claimed in claim 25 wherein in the compound of formula (1a), R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are methyl, R<sub>8</sub> is ethyl, R<sub>5</sub> and R<sub>6</sub> are propyl or butyl and R<sub>7</sub> is O or -CH<sub>2</sub>-CH<sub>2</sub>-


5 27. A silicon-based polycarbonate as claimed in claim 26 wherein R<sub>5</sub> and R<sub>6</sub> are propyl when R<sub>7</sub> is O and R<sub>5</sub> and R<sub>6</sub> are butyl when R<sub>7</sub> is -CH<sub>2</sub>-CH<sub>2</sub>-.

28. A silicon-based polycarbonate as claimed in any one of claims 25 to 27 wherein the molecular weight of the macrodiol is from about 400 to about 5000.

29. A silicon-based polycarbonate as claimed in claim 28 wherein the  
10 molecular weight of the macrodiol is from about 400 to about 2000.

30. A process for preparing the silicon-based polycarbonate macrodiol of the formula (1a) as defined in claim 25 which includes reacting a source of carbonate with either:

(i) a silicon-based diol of the formula (II)



15

(II)

wherein

R<sub>1</sub> to R<sub>7</sub> and n are as defined in formula (I) above; or

(ii) the silicon-based diol of the formula (II) defined in (i) above and a non-silicon based diol of the formula (III):

20



(III)

wherein


R<sub>9</sub> is as defined above in formula (I) of claims 1 to 22.

31. A process for preparing the silicon-based polycarbonate of claims 1 to



24 by producing the macrodiol of formula (1a) by a process as claimed in claim 30 and converting the hydroxyl group in the macrodiol of formula (1a) into other reactive functional groups.

32. A copolymer which includes a silicon-based polycarbonate segment of  
5 the formula (1b)



(1b)

wherein  $R_1$  to  $R_9$ ,  $n$ ,  $x$ ,  $y$  and  $z$  are as defined in formula (I) as claimed in any one of claims 1 to 24.

33. A polyurethane elastomeric composition which includes a silicon-based  
10 polycarbonate segment of the formula (1b) defined in claim 32.

34. Polyurethane elastomeric composition comprising a reaction product of:

- (i) a silicon-based polycarbonate of the formula (I) defined in any one of claims 1 to 24
- (ii) a diisocyanate; and
- 15 (iii) a chain extender.

35. A polyurethane elastomeric composition as claimed in claim 34 wherein the diisocyanate is selected from 4,4'-methylenediphenyl diisocyanate (MDI), methylene bis(cyclohexyl) diisocyanate (H12MDI), p-phenylene diisocyanate (p-PDI), trans-cyclohexane-1, 4-diisocyanate (CHDI) or a mixture of the cis and trans isomers, 1,6-hexamethylene  
20 diisocyanate (DICH), 2,4-toluene diisocyanate (2,4-TDI) or its isomers or mixtures thereof, p-tetramethylxylene diisocyanate (p-TMXDI) and m-tetramethylxylene diisocyanate (m-TMXDI).

36. A polyurethane elastomeric composition as claimed in claim 34 or claim 35 wherein the chain extender is selected from 1, 4-butanediol, 1, 6-hexanediol, 1, 8-octanediol, 1,9-nonanediol, 1,10-decanediol 1,4-cyclohexane dimethanol, p-xyleneglycol, 1,4-bis (2-hydroxyethoxy) benzene and 1,12-dodecanediol.

- 5 37. A polyurethane elastomeric composition comprising a reaction product of:
- (i) compounds of the formula (Ia) as claimed in claim 25 wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are methyl,  $R_8$  is ethyl,  $R_9$  is hexyl,  $R_5$  and  $R_6$  are propyl or butyl and  $R_7$  is O or  $-\text{CH}_2-\text{CH}_2-$ ;
  - (ii) MDI; and
  - 10 (iii) 1,4-butanediol.

38. A material having improved mechanical properties, clarity, processability and/or degradation resistance comprising a polyurethane elastomeric composition which includes a polycarbonate segment of the formula (Ib) as defined in claim 32.

39. Medical devices, articles or implants which are composed wholly or partly  
15 of the polyurethane elastomeric composition defined in any one of claims 33 to 37.

40. Medical devices, articles or implants as claimed in claim 39 wherein said medical devices, articles or implants comprise cardiac pacemakers, defibrillators, catheters, heart valves, cardiac assist devices, vascular grafts and implantable prostheses.

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/AU 98/00375

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																						
Int Cl <sup>6</sup> : C08G 77/448, 18/61, 18/44, C08L 83/10																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
<b>B. FIELDS SEARCHED</b>																						
Minimum documentation searched (classification system followed by classification symbols) C08G 77/448, 18/61, 18/44, 64/00, 64/02, 64/04, 64/06, 64/08, 64/10, 64/12, 64/14, 64/16, 64/18, C08L 83/10																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: IPC as above																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DERWENT: CARBONATE: POLYCARBONATE: SILOXANE; POLYSILOXANE																						
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	US 5616674 (GENERAL ELECTRIC CO.) 1 April 1997 (see the claims)	30																				
A	US 5504177 (GENERAL ELECTRIC CO.) 2 March 1995 See whole document	1-40																				
A	US 5112925 (BAYER AG.) 12 May 1992 See whole document	1-40																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier document but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 3 July 1998		Date of mailing of the international search report 14 JUL 1998																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  WARREN CHANDLER Telephone No.: (02) 6283 2251																				

## INTERNATIONAL SEARCH REPORT

Internati nal Application No.

PCT/AU 98/00375

C (Continuation)

## DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9807773 (KANEKA CORP.) 21 August 1996 See abstract	30
A	EP 216106 (BAYER AG.) 5 March 1987 See whole document	1-40
A	US 4861830 (GOLDSCHMIDT TH. AG.) 29 August 1989 See whole document	1-40
A	JP 05200827 (MITSUBISHI GAS CHEM CO INC.) 10 August 1993 See abstract	1-40
A	JP 06100684 (IDEMITSU PETROLEUM CO.) 12 April 1994 See abstract	1-40
A	AU 41924/97 (CARDIAC CRC NOMINEES, PTY LTD.) 19 September 1997 See whole document	1-40

# INTERNATIONAL SEARCH REPORT

**International Application No.**  
**PCT/AU 98/00375**

**This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.**

Patent Document Cited in Search Report	Patent Family Member				
US 5616674	CN 1150595	JP 9183837	SG 44958	EP 764676	
US 5504177	CN 1133310	EP 729997	JP 8311206	SG 35506	
US 5112925	DE 3924992	EP 411370	ES 2059914		
WO 98/07773					
EP 216106	DE 3529984	JP 62045624			
US 4861830	AT 385041	AU 548194	CA 1206668	DE 3153664	
	FR 2491938	GB 8407415	IL 62183	IT 1210997	
	JP 56136565	MX 159062	NL 8100975	ZA 8101107	
	US 4686137				
JP 06100684					
JP 5200827					

**END OF ANNEX**

